AbbVie completed the acquisition of Bretisilocin therapy of Gilgamesh Pharmaceuticals.

AbbVie, an American pharmaceutical company, completed the acquisition of Bretisilocin therapy of Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech company. Financial terms were not disclosed. "AbbVie's leadership in neuroscience and commitment to advancing innovative treatments make them the ideal partner to advance bretisilocin rapidly forward while enabling Gilgamesh to continue pursuing our broader mission of developing novel, transformative therapies for complex mental health and neurological conditions," Jonathan Sporn, Gilgamesh Pharmaceuticals CEO.